Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double-blind, multicenter, active control study of Pro-NETU for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving Cisplatin based highly emetogenic chemotherapy (HEC)

Next Previous
X
Search
Trial Profile

A phase III, randomized, double-blind, multicenter, active control study of Pro-NETU for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving Cisplatin based highly emetogenic chemotherapy (HEC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosnetupitant (Primary) ; Dexamethasone; Fosaprepitant; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CONSOLE
  • Sponsors Taiho Pharmaceutical

    • Most Recent Events

    • 16 Sep 2023 Results of pooled Pooled Analysis from JapicCTI163355, JapicCTI194691 and JapicCTI194611 Studies evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase, published in the Advances in Therapy
    • 28 Mar 2022 According to a Taiho Pharmaceutical media release, the company has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK1 receptor antagonist antiemetic drug Arokaris I.V. Infusion 235mg for gastrointestinal symptoms associated with cancer chemotherapy.
    • 18 Nov 2021 Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top